An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00528996
First received: September 12, 2007
Last updated: April 30, 2014
Last verified: April 2014

September 12, 2007
April 30, 2014
September 2007
May 2009   (final data collection date for primary outcome measure)
The primary endpoint in this study is trough FEV1 response after 24 weeks. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
The primary endpoint in this study is trough FEV1 response after 24 weeks.
Complete list of historical versions of study NCT00528996 on ClinicalTrials.gov Archive Site
  • Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks [ Time Frame: after 1, 2, 4, 8, 12, and 18 weeks ] [ Designated as safety issue: No ]
  • Trough FVC (forced vital capacity) response after 1, 2, 4, 8, 12, 18, and 24 weeks [ Time Frame: after 1, 2, 4, 8, 12, 18, and 24 weeks ] [ Designated as safety issue: No ]
  • FEV1, FVC AUC0-3h and peak response after 0, 4, 12, and 24 weeks [ Time Frame: after 0, 4, 12, and 24 weeks ] [ Designated as safety issue: No ]
  • Individual FEV1 and FVC measurements at each time point [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • trough FEV1 response on Days 3 and 5 and FEV1 and FVC at 3 minutes and 10 minutes following drug administration [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Weekly mean pre-dose morning and evening PEFR (peak expiratory flow rate) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol [salbuterol]) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Physician's Global Evaluation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Patient questionnaires: two Mahler Dyspnea Indices; St. George's Respiratory Questionnaire (SGRQ); and the SF-36 questionnaire [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Number of patients with at least one COPD exacerbation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Time to first exacerbation, as well as number of COPD exacerbations [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks
Not Provided
Not Provided
 
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Pulmonary Disease, Chronic Obstructive
  • Drug: BEA 2180 BR
  • Drug: tiotropium
Not Provided
Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respir Med. 2013 Jun;107(6):854-62. doi: 10.1016/j.rmed.2013.02.005. Epub 2013 Mar 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2080
Not Provided
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
  2. All patients must have a diagnosis of chronic obstructive pulmonary disease (P95 4381) and must meet the following spirometric criteria:

    Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 (post-bronchodilator, 30 minutes post salbutamol/albuterol) <80% of predicted normal and FEV1 less than or equal to 70% of FVC at the PFTs at Visit 1 (screening).

  3. Male or female patients 40 years of age or older.
  4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.
  5. Patients must be able to perform technically acceptable pulmonary function tests and electronic PEFR measurements, and must be able to maintain records (Patient Daily Diary) during the study period as required in the protocol.
  6. Patients must be able to inhale medication in a competent manner from the Respimat® inhaler (Appendix I)

Exclusion Criteria:

  1. Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient ability to participate in the study.
  2. Patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a significant disease as defined in exclusion criterion No. 1.
  3. Patients with a recent history (one year or less) of myocardial infarction.
  4. Patients with any unstable or life-threatening cardiac arrhythmia.
  5. Patients who have been hospitalized for heart failure within the past 3 years.
  6. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
  7. Patients with known symptomatic prostatic hyperplasia or bladder neck obstruction as defined in exclusion criteria No. 1.
  8. Patients with known narrow-angle glaucoma.
  9. Patients with asthma or a history of asthma.
  10. Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
  11. Patients with known active tuberculosis.
  12. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion No. 1.
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   Germany,   Hungary,   Korea, Republic of,   Mexico,   Poland,   Russian Federation,   Spain,   Taiwan
 
NCT00528996
1205.14, 2007-007946-42
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP